Normal Flow (TIMI-3) Before Mechanical Reperfusion Therapy Is an Independent Determinant of Survival in Acute Myocardial Infarction
Authors:
Open Access
- 7 August 2001
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 104 (6) , 636-641
Abstract
Background — Whereas survival after lytic therapy for myocardial infarction is strongly dependent on early administration, it is unknown whether the otherwise excellent outcomes in patients undergoing primary PTCA for acute myocardial infarction, in whom TIMI-3 flow rates of >90% may be achieved, can be further improved by early reperfusion. Methods and Results — Among 2507 patients enrolled in 4 PAMI trials undergoing primary PTCA, spontaneous reperfusion (TIMI-3 flow) was present in 16% at initial angiography. Compared with patients without TIMI-3 flow, those with TIMI-3 flow before PTCA had greater left ventricular ejection fraction (57±10% versus 53±11%, P =0.003) and were less likely to present in heart failure (7.0% versus 11.6%, P =0.009). Patients with initial TIMI-3 flow had significantly lower in-hospital rates of mortality, new-onset heart failure, and hypotension and had a shorter hospital stay. Cumulative 6-month mortality was 0.5% in patients with initial TIMI-3 flow, 2.8% with TIMI-2 flow, and 4.4% with initial TIMI-0/1 flow ( P =0.009). By multivariate analysis, TIMI-3 flow before PTCA was an independent determinant of survival (odds ratio 2.1, P =0.04), even when corrected for by postprocedural TIMI-3 flow. Conclusions — Patients undergoing primary PTCA in whom TIMI-3 flow is present before angioplasty present with greater clinical and angiographic evidence of myocardial salvage, are less likely to develop complications related to left ventricular failure, and have improved early and late survival. These data warrant prospective randomized trials of pharmacological strategies to promote early reperfusion before definitive mechanical intervention in acute myocardial infarction.Keywords
This publication has 22 references indexed in Scilit:
- Coronary Angioplasty with or without Stent Implantation for Acute Myocardial InfarctionNew England Journal of Medicine, 1999
- A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trialJACC, 1999
- Function and expression of endothelin-converting enzyme-1 in human vascular smooth muscleJACC, 1998
- A Prospective, Randomized Evaluation of Prophylactic Intraaortic Balloon Counterpulsation in High Risk Patients With Acute Myocardial Infarction Treated With Primary Angioplasty fn1fn1Funding for this study was provided in part by unrestricted grants from Advanced Cardiovascular Systems, Inc., Santa Clara, California; Mallinkrodt Medical, Inc., Saint Louis, Missouri; Datascope Corporation, Montvale, New Jersey; St. Jude Medical, Chelmsford, Massachusetts; and Siemens Corporation, Iselin, New Jersey.JACC, 1997
- Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: The primary angioplasty in myocardial infarction (PAMI) trialJACC, 1995
- Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patientsThe Lancet, 1994
- From myocardial salvage to patient salvage in acute myocardial infarction: The role of reperfusion therapyJACC, 1989
- THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTYThe Lancet, 1988
- Mycobacterium chelonaeWound Infections after Plastic Surgery Employing Contaminated Gentian Violet Skin-Marking SolutionNew England Journal of Medicine, 1987
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985